AbbVie and Genmab reported that Epkinly (tafasitamab-cxix) failed to prolong overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The study enrolled patients who had received at least one prior therapy; the companies disclosed that the primary endpoint of improved OS was not met. The announcement will reshape expectations for the agent’s approval pathway and commercial forecast in aggressive B‑cell malignancies. The disclosure came from the sponsors’ trial update; full data have not yet been posted in a peer-reviewed venue or regulatory filing. Investors and competitors will watch secondary endpoints and subgroup analyses for signals that could influence label strategy or combination approaches. Regulatory timing and development investments for Epkinly and any follow-on programs are likely to be reassessed in light of the negative OS readout.